MoonLake Immunotherapeutics (MLTX) Short-term Investments (2022 - 2026)

MoonLake Immunotherapeutics' Short-term Investments history runs 5 years deep, the most recent figure standing at $59.4 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 71.5% year-over-year to $59.4 million in Q1 2026; TTM through Mar 2026 was $59.4 million, a 71.5% decrease from a year earlier, with the FY2025 full-year figure at $59.5 million, down 77.78% from the prior year.
• Short-term Investments held at $59.4 million in Q1 2026 per MLTX's latest filing, from $59.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $267.6 million in Q4 2024 and bottomed at $12.9 million in Q1 2023.
• The 5-year median for Short-term Investments is $88.6 million (2024), against an average of $103.6 million.
• Across the five-year window, Short-term Investments slumped 87.23% in 2023 and jumped 586.93% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $32.6 million in 2022, then surged by 83.5% to $59.8 million in 2023, then soared by 347.2% to $267.6 million in 2024, then plunged by 77.78% to $59.5 million in 2025, then decreased by 0.03% to $59.4 million in 2026.
• Per Business Quant, the three latest MLTX Short-term Investments figures stand at $59.4 million (Q1 2026), $59.5 million (Q4 2025), and $29.7 million (Q3 2025).